LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the immediate availability in the United States of Ketorolac Tromethamine Injection (15 mg/mL) in the company’s Simplist™ ready-to-administer prefilled syringe.
Fresenius Kabi now offers ready-to-administer syringes of Ketorolac Tromethamine Injection in three strengths: 15mg/mL, 30 mg/mL and 60 mg/2mL.
“With this product addition, Ketorolac prefilled syringes are now available in three presentations, providing more ready-to-administer options to our customers,” said John Ducker, president and chief executive officer of Fresenius Kabi USA. “Similar to all Simplist syringes, this presentation of Ketorolac offers clear and consistent labeling, no assembly or point-of-care preparation and a 24 month shelf life. We look forward to bringing additional Simplist offerings to our customers.”
Ketorolac Tromethamine is a generic alternative to Toradol®. It is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting.
Prefilled injectable medicines are designed to help improve patient care and safety by decreasing the number of steps in the traditional vial and syringe injection sequence, reducing the potential risk of medication error.
For full prescribing information, including Boxed Warning, or for more information about all the Simplist ready-to-administer prefilled syringes exclusively from Fresenius Kabi, please visit www.simplist-us.com.
About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.us) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany.